The University of Massachusetts Amherst

Silicon Therapeutics

Technology Focus

Silicon Therapeutics simulates biological molecules using the laws of physics in order to predict behavior and interactions of drugs and their targets. The simulation is run on an advanced computing platform named “Neo”, which is a 400+ GPU cluster paired with advanced Intel Skylake processors that is housed at the MGHPCC.

Research Focus

Our innovative research combines deep drug discovery experience with cutting-edge capabilities in biology, chemistry, biophysics, and simulations.

Market Focus

Silicon Therapeutic’s’ technology is focused on small molecule drug design, focusing on previously “undruggable” protein targets. Recent work has focused on novel cancer and autoinflammatory treatments.

Social Impact

Our mission is to improve the lives of patients by designing novel medicines for challenging disease targets using our proprietary physics-driven discovery engine.

Publications

P. W. Snyder, J. Mecinovicì, D. T. Moustakas, S. W. Thomas, M. Harder, E. T. Mack, M. R. Lockett, A. Heìroux, W. Sherman, G. M. Whitesides. “Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase.” Proc Natl Acad Sci; 108 (44): 17889-17894 (2011)

https://www.pnas.org/content/108/44/17889.short

G. M. Sastry, M. Adzhigirey, T. Day, R. Annabhimoju, W. Sherman. “Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments.” J Comp-Aided Mol Des; 27 (3): 221–234 (2013) 

https://link.springer.com/article/10.1007/s10822-013-9644-8

Z. Cournia, B. Allen, W. Sherman. “Relative binding free energy calculations in drug discovery: recent advances and practical considerations.” J Chem Inf Model; 57 (12): 2911–2937 (2017)

https://pubs.acs.org/doi/abs/10.1021/acs.jcim.7b00564

 

Intellectual Property (IP)

STING Agonist (Cancer) – Pre-Clinical 

STING Agonist Combo (Cancer) – Pre-Clinical

Innate Immune Check-Point ADAR1 Antagonist (Cancer) – Discovery

Innate Immune Inhibitor (Autoinflammatory diseases) – Discovery

Oncogenic Phosphatase (Cancer) – Discovery

Immune Checkpoint Phosphatase (Cancer) - Discover

Progress to Date

  • 2016: $15 Million Series A funding

  • 2017: Dr. Chris Winter joins as Chief of R&D

  • 2018: Preclinical data showing Systemic Small Molecule (STING) driving Tumor Regression

  • 2019: $35 Million Series B funding

Acknowledgements

  • Chengwei Capital
  • BIDMC
  • Sequoia
Silicon Therapeutics
Contact Info

Lanny Sun
CEO

 

Woody Sherman
Chief Scientific Officer

woody@silicontx.com

 

Holly Soutter
PhD, Associate Director of Biophysics and Biochemistry

holly.soutter@silicontx.com

Website

https://silicontx.com/

https://silicontx.com/join-our-team/